CureVac CEO Franz-Werner Haas told CNBC last week that the company is planning for approval in the EU in the second quarter, depending on the results from late-stage trials evaluating the vaccine.
Those results are expected in the next few weeks, with the phase 2/3 vaccine trials now fully enrolled, according to Haas.
That includes a pivotal phase 2b/3 study in Europe and Latin America – HERALD – which has currently enrolled over 40,000 participants. Another phase 2a in Peru and Panama has also completed recruitment with 674 participants.
CureVac is also working towards addressing variants of concerns, namely the B.1.351 variant first identified in South Africa…